Comparative Pharmacology
Head-to-head clinical analysis: SELENOMETHIONINE SE 75 versus SODIUM CHROMATE CR 51.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELENOMETHIONINE SE 75 versus SODIUM CHROMATE CR 51.
SELENOMETHIONINE SE 75 vs SODIUM CHROMATE CR 51
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
None Documented
None Documented
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical